Compare ZVIA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | NERV |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 108.6M |
| IPO Year | 2021 | 2014 |
| Metric | ZVIA | NERV |
|---|---|---|
| Price | $0.94 | $2.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.67 | ★ $10.33 |
| AVG Volume (30 Days) | ★ 451.5K | 167.7K |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | $41,175,600.00 |
| Revenue This Year | $9.55 | N/A |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $0.96 | $1.96 |
| 52 Week High | $2.75 | $8.80 |
| Indicator | ZVIA | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 34.63 |
| Support Level | N/A | $1.96 |
| Resistance Level | $1.52 | $2.71 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 0.53 | 4.17 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.